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Abstract
Background: Besides conventional anticancer therapy many breast cancer patients use complementary and
alternative medicine (CAM) like the medicinal herb mistletoe (Viscum album L.). To gain more knowledge about
possible herb-drug interactions between CAM and conventional anticancer medications, in the present in vitro
study we investigated the effect of a standardized mistletoe preparation on the action of Trastuzumab, a drug used
for the treatment of Her-2 positive breast cancer.
Methods: The Her-2 positive human breast carcinoma cell line SK-BR-3 was treated with Trastuzumab. Different
doses of the drug were combined with Viscum album extract (VAE) in clinically relevant doses. Proliferation,
apoptosis, cell cycle and the secretion of vascular endothelial growth factor (VEGF) were analyzed.
Results: No inhibition of antitumor efficacy of Trastuzumab by VAE was detected. VAE and Trastuzumab, either
alone or in combination, inhibited proliferation of SK-BR-3 cells in vitro. At higher concentrations VAE induced
apoptosis, which was not observed for Trastuzumab. Cells treated with Trastuzumab underwent a G0/G1 cell cycle
arrest and cells treated with VAE a G2/M arrest. After application of the two drugs in combination both G0/G1 and
G2/M arrest was observed. VEGF secretion of SK-BR-3 cells was significantly inhibited by sole treatment with
Trastuzumab or VAE. Combined treatment of Trastuzumab and VAE at clinically relevant doses showed additive
inhibitory effects on VEGF secretion.
Conclusions: VAE did not interfere with cytostatic effects of Trastuzumab on SK-BR-3 cells in vitro. Our in vitro
results suggest that no risk of safety by herb drug interactions has to be expected from the exposition of cancer
cells to Trastuzumab and VAE simultaneously. In contrast, VAE and Trastuzumab seem to exhibit complementary
anti-cancer effects in vitro.
Keywords: Mistletoe (Viscum album L.), Iscador, Trastuzumab, Herceptin, Her-2, Drug interactions, Cytostasis,
Apoptosis, Cell cycle, VEGF
Background
Breast cancer is the most common cancer in females
worldwide with about 12 % of all new cancer cases and
25 % of all cancers in women [1, 2]. In 15–25 % of
human breast cancers the HER2 receptor, encoded by
the proto-oncogene ERBB2 is amplified. Her-2 overex-
pression has been correlated with poor clinical outcome.
The selective, fully humanized recombinant monoclonal
antibody (mAb) Trastuzumab (Herceptin) was developed
to target HER2 with high affinity. It acts as an inhibitor of
signal transduction and has been shown to decrease the
proliferation of human tumor cells that overexpress HER2
both in vitro and in vivo [3, 4]. Besides primary and meta-
static Her2 positive breast cancer, use of Trastuzumab is
approved for the treatment of HER2-overexpressing meta-
static gastric or gastroesophageal junction adenocarcinoma.
Breast cancer patients increasingly use CAM in
addition to conventional therapy with the attempt to
strengthen their immune system, prevent recurrence, to
improve quality of life and feel more in control. With a
prevalence of 40-80 % CAM use is high [5–7]. In Europe
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especially the application of mistletoe preparations is
widespread [8–10]. Extracts derived from mistletoe (Vis-
cum album) have been shown to display anti-tumoral,
anti-angiogenetic and immune-potentiating activities
[11–14]. Mistletoe preparations are used either alone or
in combination with chemo-, radio- and hormonal and
probably with new molecular targeted therapies to treat
cancer or to lessen the side effects of anticancer drugs.
Clinical studies suggest the association of mistletoe
treatment with a better survival, a reduction of side ef-
fects of traditional therapies and with an increase of
quality of life [15–18].
In a former in vitro study we demonstrated that
mistletoe extracts did not influence the cytostatic and
cytotoxic activity of several common conventional che-
motherapeutic drugs when applied in concentrations
typical for clinical use [19].
The aim of the present study was to investigate pos-
sible effects of clinically relevant doses of a standardized
Viscum album extract (VAE) on the in vitro efficacy of
Trastuzumab with regard to proliferation, apoptosis, cell
cycle kinetics and production of vascular endothelial
growth factor (VEGF) using the Her-2 positive cell line
SK-BR-3.
Methods
Mistletoe extracts and drugs
The aqueous, fermented mistletoe preparation Iscador M
spec. 5 mg (VAE, host tree Malus domestica, Lot 1109/
2103/2, total mistletoe lectin concentration 287 ng/ml)
was obtained from Iscador AG (Arlesheim, Switzerland).
Vials of Iscador M spec. 5 mg, stored at 4 °C were used as
VAE stock solution.
Trastuzumab (Herceptin®) (Lot. B4009) was kindly pro-
vided by Roche Pharma AG Switzerland. Stock solution
(15 mg/ml in deionized water) was stored at - 20 °C.
Cell culture
Human breast carcinoma cell line SK-BR-3 was obtained
from DSMZ (German Collection of Microorganisms and
Cell Cultures, Braunschweig, Germany).
SK-BR-3 cells were cultured in McCoy’s 5A Medium
(Sigma-Aldrich) supplemented with 20 % FBS, 2 mM L-
Glutamine and 1 % Penicillin - Streptomycin in a hu-
midified atmosphere with 5 % CO2 at 37 °C. Cell line
was maintained in exponential growth and cells from
subconfluent monolayers were harvested by trypsin-
EDTA (Sigma-Aldrich) to carry out the experiments. For
measurement of the parameters, the cell cultures were
used within 6–8 weeks after thawing.
Proliferation assay
Proliferation was indirectly assessed using the cell prolif-
eration reagent WST-1 (Roche, Mannheim, Germany).
Cells (1.5 x 104 in 100 μl) were plated in triplicates in
96-well plates. After 4–6 h to allow attachment, the
drugs were added in various concentrations (see below).
Proliferation rate was measured after 4 h of incubation
with the WST-1 reagent in triplicate. The upper limit of
absorbance was 2.0 - 2.1. Values are given in percent in-
hibition of proliferation relative to untreated control.
Cell death analysis
Apoptosis/necrosis was measured using the Annexin V-
FITC Apoptosis Detection Kit I (BD Biosciences Phar-
mingen™, San Diego, CA, USA). Briefly: 2 x 105 cells
were incubated with Annexin V-FITC and 7-AAD at
room temperature in the dark. Thereafter, the samples
were analysed in a flow cytometer (FACS Calibur, BD
Biosciences, San Jose, CA). Early apoptotic cells:
Annexin V-FITC positive and 7-AAD negative. Late
apoptotic/necrotic cells: Annexin V-FITC positive and
7-AAD positive. Values are given in percent of total cell
number.
Cell cycle analysis
Cell cycle analysis was performed using the CycleTest™
Plus DNA reagent Kit (BD Biosciences, San Jose, CA)
according to manufacturer’s instructions. DNA QC par-
ticles were used for quality control. Data were analyzed
using the FlowJo 7.6.1 software (Ashland, OR, USA).
Drug concentrations in the assays
Preceding the actual experiments the optimal concen-
tration range and the optimal incubation time regard-
ing treatment efficacy was determined for Trastuzumab
using the WST-1 proliferation assay (data not shown).
The concentration range for Trastuzumab was higher
than the corresponding dose of 2-4 mg/kg used in
clinic [20].
In the main experiments, Trastuzumab was added to
culture medium at following concentrations: 0, 0.1, 1.0,
10 and 100 μg/ml. Depending on the assay, each dose of
the drug was combined with 0, 0.1, 1.0, 10 or 100 μg/ml
of VAE for measuring proliferation, apoptosis/necrosis,
cell cycle and VEGF secretion. Typical clinical Iscador
concentrations for subcutaneous application are 0.1 and
1 μg/ml, roughly corresponding to an injection of 5 mg
Iscador when referring to the body weight and the
amount of circulating blood, respectively. Concentra-
tions of about 10 μg/ml correspond to doses used for
intravenous Iscador applications. Parameters were mea-
sured after the appropriate incubation time.
VEGF ELISA
2.5 x 105 SK-BR-3 cells were plated in 6-well plates.
After 4-6 h to allow attachment, the drugs were added
in various concentrations in a final volume of 2 ml per
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well. Cell culture supernatants were collected after 3 days
(3d) of incubation, centrifuged and stored in aliquots at
−80 °C until analysis. VEGF-A concentrations were de-
termined using a commercial Human VEGF ELISA kit
(Sigma-Aldrich, MO, USA) according to manufacturer's
instructions. The detection limit was 10 pg/ml.
Data analysis
Three independent experiments were carried out for
each combination of Trastuzumab and mistletoe extract.
Data were analyzed with full 3-way analysis of variance
(ANOVA, Type 6 decomposition) using Statistica 6.0
(Statsoft Inc., Tulsa, USA). For pairwise comparisons,
the protected Fisher LSD-test was used. This procedure
gives a good safeguard against false-positive as well as
false-negative results [21]. Limit of significance was de-
fined as p < 0.05.
Results
Proliferation
The growth kinetic analysis of SK-BR-3 cells revealed
different effects of VAE and Trastuzumab when used as
single agents. A dose dependent anti-proliferative effect
of VAE was observed at concentrations ≥10 μg/ml after
3d of incubation. After 7d a significant growth inhibition
of 60 % with the clinically relevant concentration 1 μg/
ml was detected and no proliferating cells were left at
VAE concentrations of 10 and 100 μg/ml. 0.1 μg/ml
VAE did not significantly affect the proliferation of
tumor cells (Fig. 1a).
Figure 1b presents mean proliferation values of the
breast carcinoma cell line SK-BR-3 treated with differ-
ent concentrations of Trastuzumab. The maximal
cytostatic effect attained by the treatment with Tras-
tuzumab alone was 63 % after 7d of incubation. With
1 μg/ml Trastuzumab a plateau of inhibition was
reached resulting in no further enhancement at con-
centrations of 10 and 100 μg/ml.
After simultaneous application of VAE and
Trastuzumab, concentrations of 1–100 μg/ml VAE
significantly enforced the antiproliferative effect of all
Trastuzumab concentrations applied (p < 0.01),
whereas 0.1 μg/ml did not show any modulation
(Fig. 1c, d).
Fig. 1 Dose response effect of VAE, Trastuzumab and their combinations on the proliferation of SK-BR-3 cells. Proliferation inhibition by (a) VAE
treatment after 3d and 7d, (b) Trastuzumab treatment after 3d and 7d and combined VAE and Trastuzumab treatment after (c) 3d and (d) 7d, are
shown. Cell growth kinetic was assessed with the WST-1 assay. Results are presented as mean ± SE from three independent experiments
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Apoptosis
To characterize the type of cell death induced by VAE
and Trastuzumab, respectively, Annexin V/7-AAD dual
staining was used to evaluate the apoptotic cells. VAE
concentrations between 0.1 and 1 μg/ml had no signifi-
cant effect on the viability of SK-BR-3 cells; VAE at
10 μg/ml induced apoptosis (p < 0.001, F-test, Fig. 2).
With 10 μg/ml VAE after 3d the proportion of early
apoptotic cells was elevated from 7.1 % in the un-
treated control to 32.8 % and that of late apoptotic/
necrotic cells from 7.0 % in control to 12.1 % (Fig. 3a,
b). After 7d the proportion of early apoptotic cells
raised from 9.0 % in the control to 17.4 % and that
of late apoptotic/necrotic cells from 18.7 % in control
to 78.7 %, respectively (Fig. 3c, d).
In our experimental setup Trastuzumab alone did not
exert a dose dependent pro-apoptotic or cytotoxic effect.
After 3d and after 7d treatment of SK-BR-3 cells with
concentrations of Trastuzumab between 0.1 and 100 μg/
ml, the proportions of apoptotic or dead cells remained
unaltered compared to the untreated control (p > 0.05,
F-test) and Trastuzumab did not significantly alter VAE
induced apoptosis (p > 0.8, F-test for interaction, Fig. 3),
though there was a tendency that Trastuzumab enforced
the pro-apoptotic effect of 10 μg/ml VAE after 3 days
(Fig. 3a).
Cell cycle analysis
VAE at 10 μg/ml influenced cell cycle kinetics by in-
ducing a significant G2/M accumulation of 11 vs. 7 %
in control (P < 0.001, Fig. 4a). The proportion of S-
phase cells declined from 31 to 24 %. Lower VAE
concentrations had no effect. VAE did not induce a
G0/G1 accumulation at any concentration (p > 0.28,
F-test).
As shown in Fig. 4b, Trastuzumab induced a dose
dependent significant accumulation of SK-BR-3 cells
in G0/G1 cell cycle phase (p < 0.001, F-test). The
maximal percentage of cells found in G0/G1 phase
was 71 % after treatment with 100 μg/ml Trastuzu-
mab, compared to 60 % in the control. Trastuzumab
did not induce a G2/M accumulation (p > 0.12, F-
test).
Simultaneous treatment of cells with 10 μg/ml VAE
and Trastuzumab induced a block in both cell cycle
phases, G0/G1 (67 % with 1 μg/ml Trastuzumab and
66 % with 10 μg/ml Trastuzumab) and G2/M (10 %
with 1 μg/ml Trastuzumab and 13 % with 10 μg/ml
Trastuzumab) (Fig. 4c, d). VAE concentrations of 0.1
and 1 μg/ml did not influence the effect of Trastuzu-
mab on cell cycle. There was no statistically significant
interaction in the ANOVA model, which means that
the effects of Trastuzumab and VAE were additive.
Fig. 2 Apoptosis induction in SK-BR-3 cells by VAE. Flow cytometric analysis of apoptotic death in SK-BR-3 cells labelled with annexin-V FITC and
7-AAD after 3d (top) and after 7d (bottom) exposure to 10 μg/ml Trastuzumab in combination with 0 – 10 μg/ml VAE. This figure is representative
of three independent experiments. The percentages in the graphs represent the percentage of cell numbers in each quadrant. Q1 and Q2: late
apoptotic/necrotic cells, Q3: early apoptotic cells, Q4: living cells
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VEGF production
We assessed whether treatment with VAE and/or
Trastuzumab were able to reduce VEGF production in
SK-BR-3 cells. Untreated SK-BR-3 cells were found to
secrete appreciable quantities of VEGF (approximately
1500 pg/ml/2.5×105 seeded cells) into the media.
Both VAE and Trastuzumab reduced VEGF produc-
tion (p < 0.001, F-test) without a significant inter-
action in the ANOVA model (p = 0.22), meaning that
the effects on VEGF were independent (additive). As
shown in Fig. 5, 1 μg/ml VAE reduced VEGF produc-
tion to 71 % (p < 0.01), whilst Trastuzumab induced a
decrease in VEGF production, which reached about
61 % at the concentrations of 1 and 10 μg/ml
antibody and 48 % at the concentration of 100 μg/ml
(p < 0.001 for all concentrations). Co-treatment with
1 μg/ml VAE and Trastuzumab revealed the most
pronounced effects.
Proliferation inhibition is a possible underlying cause for
lower VEGF concentrations in culture supernatants of
treated cells. We investigated this hypothesis by calculat-
ing VEGF production relative to proliferation (Fig. 1) for
the relevant concentrations of VAE and Trastuzumab. In
this evaluation, application of 1 μg/ml VAE led to a signifi-
cant reduction of VEGF production (86 %, p < 0.05);
Trastuzumab did not yield any significant effects at any
concentration applied (p > 0.15).
Discussion
In our in vitro study we investigated the interaction be-
tween Trastuzumab, a monoclonal antibody used for the
treatment of Her-2 positive breast cancer and an aque-
ous fermented mistletoe extract, frequently used by can-
cer patients as supportive therapy. No inhibition of
antitumor efficacy of Trastuzumab by VAE was detected
in any of our experimental setups. The same applies to
Fig. 3 Apoptosis induction in SK-BR-3 cells. Mean values (±SE) of (a) early apoptosis and (b) late apoptosis/necrosis after 3d and of (c) early
apoptosis and (d) late apoptosis/necrosis after 7d treatment with different concentrations of Trastuzumab combined with different concentrations
of VAE are presented
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the antitumor efficacy of VAE, which was not inhibited
by Trastuzumab. When used individually, VAE and
Trastuzumab showed dissimilar anti-proliferative effects.
The growth inhibitory effect of Trastuzumab was associ-
ated with G0/G1 accumulation but not with apoptosis.
VAE alone and in combination with Trastuzumab
revealed a distinct pro-apoptotic activity and a G2/M ar-
rest. Both Trastuzumab and VAE significantly inhibited
VEGF production, alone as well as in combination.
Little is known so far about possible drug interactions
of mistletoe preparations with Trastuzumab. In a retro-
spective case series study examining the tolerability of
the simultaneous treatment with mistletoe preparations
and Herceptin in nine breast cancer patients no new
side effects that could be attributed to the well tolerated
combined treatment were observed. However an
increased incidence of mild reactions consisting of well-
known side effects of either mistletoe or Herceptin treat-
ment was noted and therefore a special attention was
recommended (A.P. Simões-Wuest, personal communi-
cation). A prospective study would provide more conclu-
sive information.
The aim of our study was to investigate if clinically
relevant doses of VAE interfere with Trastuzumab in
vitro by influencing its anti-tumoral efficacy on prolifer-
ation, cytotoxicity, cell cycle progression and VEGF pro-
duction of a Her2 positive breast cancer cell line.
Trastuzumab and VAE as well as their combinations
Fig. 4 SK-BR-3 cell cycle analysis of cells treated with (a) VAE (b) Trastuzumab (c) 1 μg/ml Trastuzumab and VAE and (d) 10 μg/ml Trastuzumab
and VAE. Cells were harvested after 3d, fixed, stained and analyzed for DNA content by flow cytometry. The distribution and percentage of cells
in G0/G1, S and G2/M phase of the cell cycle are indicated. Results are presented as mean values from three independent experiments. (SE values
are omitted for clarity). Significance values are given relative to the VAE and Trastuzumab untreated controls (**p < 0.01, ***p < 0.001).
Discrepancies from 100 % can be attributed to slight gating differences and the display of mean values
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induced dose and time dependent anti-proliferative ef-
fects on SK-BR-3 cells. Our results regarding growth in-
hibition and lack of apoptosis induction by Trastuzumab
alone are comparable to data shown previously [22–25].
Depending on the treatment time VAE doses ≥1 μg/ml
induced a 60 % and ≥10 μg/ml a total inhibition of cell
proliferation. Concomitant treatment already with the
clinically relevant dose of 1 μg/ml VAE could lead to an
augmentation of Trastuzumab induced cytostasis for
about 13-15 %.
Much of the Trastuzumab induced growth-inhibitory
effects might be due to a transient cell cycle arrest.
Consistent with former studies we observed a distinct
G0/G1 accumulation in Trastuzumab treated SK-BR-3
cells [26, 27]. As an initial effect of specific antibodies on
Her-2 receptor signaling, a redirection of cyclin-dependent
kinase (Cdk) inhibitor p27 (also known as KIP1) onto
Cdk2 complexes was proposed, resulting in the inhibition
of G1/S progression. The p27-Cdk2 complex accumula-
tion was correlated with reduced protein levels of D-type
cyclins and transcription factor c-Myc [28].
Growth inhibition by higher VAE concentrations
detected in our study could be strongly related to pro-
apoptotic activity. Induction of apoptosis is a well-
defined mechanism exerted by mistletoe lectins (ML).
One of the constituents of VAE is ML-I, a heterodimeric
ribosome-inactivating protein II (RIP II) composed of an
A-chain with the capacity to depurinate a critical adeno-
sine in the 28S ribosomal RNA and a sialic acid-specific
B chain that binds to cell surfaces and facilitates intern-
alization of the A-chain [29]. ML, like other type II RIPs
induce cell apoptosis in vitro and in vivo probably via an
intracellular pathways described as “ribotoxic stress re-
sponse” that directly targets mitochondria and leads to
apoptosis through a stress-mediated signalling pathway
[30–32]. The ML-I induced apoptosis is reported to be
receptor-independent. Cytochrome c is rapidly released
from mitochondria into the cytosol accompanied by pro-
teolytic activation of caspase-8, −9, −3 and −2 and de-
creased expression of anti-apoptotic molecules [33, 34].
If the ribosome inhibiting activity of ML or another
mechanism or constituent is responsible for the prolifer-
ation inhibiting effect of 1 μg/ml VAE, a concentration
were no apoptosis induction was observed, has to be
evaluated.
VAE at 10 μg/ml induced a G2/M arrest and simultan-
eous treatment with Trastuzumab and 10 μg/ml VAE in-
duced the accumulation of SK-BR-3 cells in both G0/G1
and G2/M cell cycle phases. The G2/M phase arrest
with a decline in the proportion of S-phase cells after
treatment with VAE was observed in parallel to the rise
of apoptotic cell content. It is known, that the processes
of cell cycle progression and programmed cell death use
and control shared factors like p53, p21, RB, c-Myc and
several cyclin-dependent kinases (Cdks) and their regu-
lators [35]. Activated p53 can cause apoptosis, G0/G1
arrest but also functions at the G2/M checkpoint [36]
but in breast cancer SK-BR-3 cell line the p53 gene is
mutated [37]. The investigation of recombinant ML ef-
fects on tumor cell proliferation in p53-wild-type and
-deficient murine embryo fibroblasts indicated a pre-
dominantly p53-independent mechanism of apoptosis
induction by rML [38]. Changes in cell cycle may be as
well a p53-independent secondary effects of ribosome
inhibition and ribotoxic stress by VAE that block entry
into mitosis. G2/M arrest and apoptosis can result from
upregulation of p53, p21, Chk1 and Chk2 (checkpoint
kinases 1 and 2) and downregulation of cyclin B1 or
cyclin D1 [35, 39, 40]. Miyoshi et al. demonstrated a
marked elevation of p21 mRNA and protein upon
exposure of a human myeloid cell line to ML (VAA,Vis-
cum album agglutinin) [41]. P21 participates in the
maintenance of cells in G1-phase arrest but also in G2/
M through multiple mechanisms [42, 43]. In squamous
cell carcinoma cell lines VAE treatment led to a substan-
tial decrease in the expression level of Cyclin D1 [44].
Cyclin D1 performs a critical cell cycle regulatory func-
tion during G2 phase [45] and silencing of Cyclin D1
also had an effect on apoptosis induction in several
squamous cell carcinoma cell lines [46].
In summary our results suggest that Trastuzumab and
VAE influenced different cell cycle regulators in SK-BR-
3 cells whereby the G2/M arrest induced by VAE
Fig. 5 Inhibitory effect of Trastuzumab, VAE and their combinations
on VEGF production of SK-BR-3 human breast carcinoma cells in
vitro. VEGF was measured by ELISA in cell culture supernatants after
3d of treatment. Results are presented as mean ± SE from three
independent experiments
Weissenstein et al. BMC Complementary and Alternative Medicine  (2016) 16:271 Page 7 of 10
seemed to be correlated to apoptosis related events. Mo-
lecular investigations could provide further confirmation
on this subject.
One of the fundamental physiological processes of
tumor growth is angiogenesis, mediated by pro- and
anti-angiongenic factors [47, 48]. Her-2 signaling affects
the expression of angiogenic factors like VEGF,
Interleukin-8 and thrombospondin-1 [49]. VEGF stimu-
lates endothelial cell proliferation and migration and
causes the degradation of the basement membrane in
microvessel walls. In cancer cells VEGF is supposed to
promote proliferation, survival and invasiveness [50, 51].
In our experiments we demonstrated a significant inhib-
ition of VEGF production by SK-BR-3 cells treated with
Trastuzumab. Concomitant treatment with VAE at clin-
ically relevant doses did not negatively affect the inhibi-
tory efficacy of Trastuzumab, co-treatment with 1 μg/ml
VAE revealed even lower VEGF values. In SK-BR-3 cell
cultures treated with Trastuzumab the inhibition of
VEGF correlated with growth reduction and seemed not
to be a primary effect. Several in vivo and in vitro studies
demonstrated that the treatment with Her-2 neutralizing
antibodies like Trastuzumab induced a down-regulation of
VEGF mRNA and protein levels in Her-2-overexpressing
tumors resected from xenografted mice as well as in Her-
2 overexpressing breast tumor cell lines, associated with
inhibition of tumor growth and vessel formation [49, 52].
Sole VAE caused a significant VEGF diminution that
was mainly independent of proliferation inhibition what
indicates a direct suppressive effect of VAE on VEGF ex-
pression besides the reduction of VEGF protein content
in cell culture media due to lower cell densities. If this
effect is specific or a consequence of ribosome inhibiting
events has to be proven. Varying results on the effect of
mistletoe on angiogenesis exist. Inhibitory impact of
VAE on vessel development in vitro and in vivo was as-
sociated with apoptosis induction [53] but in another
study VAE-treated glioblastoma cells down-regulated
central genes involved in glioblastoma progression and
malignancy, among others VEGFA, without parallel
cytotoxicity and apoptosis [54].
In our in vitro study we intended to contribute infor-
mation about possible interactions of VAE with Trastu-
zumab. We addressed some of the mechanisms of action
proposed for Trastuzumab [55] using a Her2 positive
breast cancer cell line. One of the limitations of working
with cell lines is, that interaction and protection mecha-
nisms otherwise available from the donor organism are
eliminated. Although we could not detect pro-apoptotic
activity of Trastuzumab in our experiments it has been
shown that neoadjuvant treatment with Trastuzumab in
vivo induced some apoptosis in primary breast cancers
[56]. In addition to the direct effects on cancer cells,
there was evidence that antibody-dependent cellular
cytotoxicity (ADCC) plays an important role in the anti-
tumor activity of Trastuzumab, a mechanism we could
not explore in our in vitro experiments. In vivo, specific
immune cells could recognize and lyse tumor cells
coated with the antibody. As mistletoe was reported to
exert immune-modulating activities that may enhance
the host defense system against tumors it would be in-
teresting to investigate if ADCC could be fostered by
mistletoe co-treatment.
Conclusions
Aqueous, fermented mistletoe extract did not attenuate
the anti-tumor activity of Trastuzumab in vitro when ap-
plied in concentrations typical for clinical use. We inves-
tigated the effects of VAE concomitant to Trastuzumab
on proliferation, apoptosis induction, cell cycle progres-
sion and VEGF expression in a Her-2 overexpressing
breast cancer cell line and could show concentration
dependent additive effects. Our in vitro results suggest
that VAE can be used without impairment of Trastuzu-
mab efficacy. Further studies should be performed to
complete the knowledge about drug interactions and
patient safety and to investigate if the positive additive
effects by VAE treatment concomitant to Trastuzumab
could also be found in vivo.
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